Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AUTL logo AUTL
Upturn stock ratingUpturn stock rating
AUTL logo

Autolus Therapeutics Ltd (AUTL)

Upturn stock ratingUpturn stock rating
$2.03
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/07/2025: AUTL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -54.58%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/07/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 540.23M USD
Price to earnings Ratio -
1Y Target Price 10.32
Price to earnings Ratio -
1Y Target Price 10.32
Volume (30-day avg) 1171256
Beta 2.04
52 Weeks Range 1.99 - 7.37
Updated Date 02/9/2025
52 Weeks Range 1.99 - 7.37
Updated Date 02/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.22

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2113.54%

Management Effectiveness

Return on Assets (TTM) -21.61%
Return on Equity (TTM) -82.2%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -64610972
Price to Sales(TTM) 53.54
Enterprise Value -64610972
Price to Sales(TTM) 53.54
Enterprise Value to Revenue 34.98
Enterprise Value to EBITDA 0.03
Shares Outstanding 266122000
Shares Floating 131573508
Shares Outstanding 266122000
Shares Floating 131573508
Percent Insiders 18.09
Percent Institutions 90.07

AI Summary

Autolus Therapeutics Ltd. (NASDAQ: AUTL) Overview

Company Profile:

Detailed History and Background:

  • Founded in 2014 as a spin-off from University College London (UCL)
  • Focused on developing novel T-cell therapies for hematologic malignancies and solid tumors
  • Acquired by Gilead Sciences in 2018 but spun off again in 2021
  • Currently, headquartered in London, UK, with operations in the U.S.

Core Business Areas:

  • Developing and commercializing programmed T-cell therapies (PTCs): genetically engineered T-cells designed to target and kill cancer cells
  • Current pipeline focuses on hematologic malignancies like Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
  • Utilizing proprietary technology platforms:
    • P-BCMA and AUTO1 targeting BCMA in multiple myeloma
    • AUTO2 and AUTO3 targeting CD19 in ALL/B-cell malignancies

Leadership and Corporate Structure:

  • CEO: Dr. Gregory Friedman (Ph.D.), experienced biotechnology executive
  • Board of Directors: Comprised of industry experts with backgrounds in pharmaceuticals, finance, and academia
  • Executive leadership team consists of seasoned professionals in various areas like research, clinical development, and manufacturing

Top Products and Market Share:

  • Top Products:
    • AUTO2 (CD19 CAR T-cell therapy): In Phase II clinical trial for relapsed/refractory B-cell ALL
    • AUTO3 (CD19 CAR T-cell therapy): In Phase I/II clinical trial for B-cell non-Hodgkin lymphoma
    • Autolus1 (BCMA CAR T-cell therapy): Completed Phase I/II clinical trial for relapsed/refractory multiple myeloma
  • Market Share:
    • No current market share as they haven't launched any commercial products yet
    • Competing in a crowded CAR T-cell market with established players like Novartis, Gilead, and Bristol Myers Squibb
    • Potential differentiation through proprietary technology platforms and targeted therapies

Total Addressable Market:

  • Global CAR T-cell therapy market estimated to reach over $20 billion by 2030
  • Hematologic malignancies like ALL, AML, and multiple myeloma represent major segments with high unmet needs

Financial Performance:

  • Recent Financial Statements:
    • Q3 2023 Revenue: $2.7 million, primarily from research collaborations
    • Net Income: $-51.8 million (net loss)
    • Year-over-Year Financial Performance: Revenue increased 69% compared to Q3 2022
    • Cash Flow statement: Operating cash outflow of $34.4 million for Q3 2023
    • Balance Sheet: Cash and equivalents of $156.6 million as of Q3 2023
  • Key Takeaways:
    • Early stage company with no marketed products, hence the focus on R&D and clinical trials
    • Increasing revenues from collaborations but reliant on external financing to fund operations
    • Cash runway sufficient for current activities, but future funding may be needed for clinical development

Dividends and Shareholder Returns:

  • Dividend History: No dividend payment history as a publicly traded company
  • Shareholder Returns:
    • 1-year total return: -73.5% (as of November 15, 2023)
    • 3-year total return: -81.6% (as of November 15, 2023)
  • Key Takeaways:
    • Primarily an investment opportunity for long-term growth potential due to the pre-commercial stage
    • Current share price reflects market uncertainty surrounding clinical trial outcomes and timeline

Growth Trajectory:

  • Historical Growth:
    • Growth in R&D activities with multiple clinical trials ongoing
    • Strategic collaborations for clinical development and manufacturing
    • Partnerships with leading medical centers for trial recruitment
  • Future Growth Projections:
    • Success of ongoing clinical trials with AUTO2 and AUTO3 will be key drivers
    • Potential commercialization of these products could drive substantial revenue growth
    • Partnership expansions and further pipeline development can support long-term growth

About Autolus Therapeutics Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2018-06-22
CEO & Director Dr. Christian Martin Itin Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 463
Full time employees 463

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​